Transitions of multifocal electroretinography following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy
- 125 Downloads
To investigate the changes in the multifocal electroretinography (ERG) after combined intravitreal bevacizumab and photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV) patients. Thirteen eyes of 13 patients were included in the study. The latencies and average response densities of all the six ring retinal regions were measured and compared before treatment and 1, 3, and 6 months after treatment. The latencies of the N1 and P1 waves in all the six rings remained unchanged compared with pre-treatment. Significant increase of average response densities of both P1 in ring 1 (P = 0.023) and N1, P1 in ring 2 (P = 0.028 and 0.046, respectively) were detected at 3 months post-treatment. The increase of P1 amplitude densities in ring 1 (P = 0.015) and N1, P1 amplitude densities in ring 2 (P = 0.031 and 0.034, respectively) were also significant at 6 months post-treatment. In conclusion, combined intravitreal bevacizumab and PDT is associated with an increase of multifocal ERG centrally in PCV patients.
KeywordsPolypoidal choroidal vasculopathy Photodynamic therapy Bevacizumab Multifocal electroretinography
This study was supported by the National Basic Research Program of China (grant no. 2007CB512206).
- 6.Ziemssen F, Luke M, Bartz-Schmidt KU, Gelisken F (2008) Time-dependent effects on contrast sensitivity, near and distance acuity: difference in functional parameters? (Prospective, randomized pilot trial of photodynamic therapy versus full macular translocation). Graefes Arch Clin Exp Ophthalmol 246:653–659. doi: 10.1007/s00417-007-0726-y PubMedCrossRefGoogle Scholar
- 12.Matsuoka M, Ogata N, Otsuji T, Nishimura T, Takahashi K, Matsumura M (2004) Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. Br J Ophthalmol 88:809–815. doi: 10.1136/bjo.2003.032466 PubMedCrossRefGoogle Scholar
- 20.Imai H, Honda S, Nakanishi Y, Yamamoto H, Tsukahara Y, Negi A (2006) Different transitions of multifocal electroretinogram recordings between patients with age-related macular degeneration and polypoidal choroidal vasculopathy after photodynamic therapy. Br J Ophthalmol 90:1524–1530. doi: 10.1136/bjo.2006.092783 PubMedCrossRefGoogle Scholar
- 21.Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report. Arch Ophthalmol 117:1329–1345Google Scholar
- 24.Chan WM, Liu DT, Lai TY, Li H, Tong JP, Lam DS (2005) Extensive submacular haemorrhage in polypoidal choroidal vasculopathy managed by sequential gas displacement and photodynamic therapy: a pilot study of one-year follow up. Clin Exp Ophthalmol 33:611–618. doi: 10.1111/j.1442-9071.2005.01105.x CrossRefGoogle Scholar
- 26.Imai H, Honda S, Nakanishi Y, Yamamoto H, Tsukahara Y, Negi A (2006) Different transitions of multifocal electroretinogram recordings between patients with age-related macular degeneration and polypoidal choroidal vasculopathy after photodynamic therapy. Br J Ophthalmol 90:1524–1530. doi: 10.1136/bjo.2006.092783 PubMedCrossRefGoogle Scholar
- 32.Moschos MM, Brouzas D, Apostolopoulos M, Koutsandrea C, Loukianou E, Moschos M (2007) Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study. Multifocal-ERG after use of bevacizumab in ARMD. Doc Ophthalmol 114:37–44. doi: 10.1007/s10633-006-9036-7 PubMedCrossRefGoogle Scholar